Search clinical trials for: Peginterferon alfa-2b (SCH 54031)

Total 872 results

Merck Sharp & Dohme LLC

Completed

PegIntron Injection Surveillance Plan (Study P04123)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

Chronic Hepatitis C | Liver Fibrosis
Merck Sharp & Dohme LLC

Completed

Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)

Cirrhosis | Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)

Hepatitis D, Chronic | Hepatitis B, Chronic
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

Renal Insufficiency
Merck Sharp & Dohme LLC

Completed

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

Melanoma
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Melanoma
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) (PRACTICE)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED) (ADEQUATION)

Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Completed

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

Liver Cirrhosis | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Withdrawn

An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN) (PEGIMPACT)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)

Fibrosis | Liver Cirrhosis | Hepatitis | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) (APEGIN)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) (PROVIDE)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) (SATISFACTION)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)

Hepatitis C, Chronic
Schering-Plough

Completed

Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)

Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)

HIV Infections | Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC

Completed

Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)

Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (SPRINT-2)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)

Hepatitis C, Chronic | Hepacivirus
Schering-Plough

Completed

PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336) (VIDA)

Hepatitis C, Chronic | Genotype 1 | HCV-1
Merck Sharp & Dohme LLC

Completed

Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Terminated

The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)

HIV Infections | Hepatitis C | Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) (@dhere)

Hepatitis C | Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) (SUPPORT)

Substance Abuse, Intravenous | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)

Hepatitis C
Biocad

Completed

An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Hepatitis | Hepatitis C | Hepatitis C/ Human Immunodeficiency Virus Coinfection

Russian Federation
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)

Hepatitis C | Hepatitis C, Chronic
Xiamen Amoytop Biotech Co., Ltd.
Peking University People's Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PEGIFN)

Chronic Hepatitis C

China
Merck Sharp & Dohme LLC

Terminated

Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) (RE-CHUT)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632) (ATHENAS)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

HIV Infections | Hepatitis C | HCV Infection

3

Subscribe